Enter assignee name

EPO Patents = 11

Trademarks = 1

Forward Citations = 45

Loading Chart...

4 inventors (with patents filed for the assignee):

Michael Strupp (14 out of 14 patents)

Mallory Factor (8 out of 8 patents)

Michiko Mann (1 out of 1 patent)

4. Grant Charles Churchill (1 out of 1 patent)

5. Taylor Fields (0 patent)

18 patents: Sort by Forward Citations

1. 12715839 - Branched-chain amino acid derivatives to treat disease (2026-08-25),

2. 12697316 - Combination therapy with acetyl-leucine and miglustat (2026-08-04),

3. 12667550 - Treatment of late-onset neurodegenerative diseases in heterozygous NPC1 gene mutation carriers (2026-06-30),

4. 12458614 - Therapeutic agents for improved mobility and cognitive function and for treating neurodegenerative diseases and lysosomal storage disorders (2025-11-04),

5. 12433863 - Pharmaceutical compositions and uses directed to lysosomal storage disorders (2025-10-07),

6. 12433862 - Pharmaceutical compositions and uses directed to lysosomal storage disorders (2025-10-07),

7. 12329733 - Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function (2025-06-17),

8. 12145899 - Deuterated analogs of acetyl-leucine (2024-11-19),

9. 12144792 - Therapeutic agents for neurodegenerative diseases (2024-11-19),

10. 12121513 - Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject (2024-10-22),

11. 11998518 - Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function (2024-06-04),

12. 11793782 - Therapeutic agents for neurodegenerative diseases (2023-10-24),

13. 11690830 - Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject (2023-07-04),

14. 11660279 - Therapeutic agents for treating restless leg syndrome (2023-05-30),

15. 11471434 - Treatment for migraine (2022-10-18),

Intrabio Limited is a biotechnology company focused on developing innovative solutions for the treatment of neurodegenerative diseases. With a strong emphasis on research and development, Intrabio is committed to advancing therapies that address the underlying causes of these debilitating conditions. Through collaboration with leading scientists and medical professionals, Intrabio aims to make a meaningful impact on the lives of patients worldwide.

Profile summary based on public USPTO records.